Human Pathology
Volume 41, Issue 3 , Pages 415-424 , March 2010

PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma

Received 24 February 2009 ,Revised 15 May 2009 ,Accepted 21 May 2009.

References 

  1. Abe Y, Matsumoto S, Kito K, Ueda N. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem. 2000;275:21525–21531
  2. Gaudet S, Branton D, Lue RA. Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci U S A. 2000;97:5167–5172
  3. Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 2006;66:9186–9195
  4. Zhu F, Zykova TA, Kang BS, et al. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology. 2007;133:219–231
  5. Ayllon V, O'Connor R. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response. Oncogene. 2007;26:3451–3461
  6. Abe Y, Takeuchi T, Kagawa-Miki L, et al. A mitotic kinase TOPK enhances Cdk1/cyclin B1-dependent phosphorylation of PRC1 and promotes cytokinesis. J Mol Biol. 2007;370:231–245
  7. Metairie S, Lucidi V, Castaing D. Intra-hepatic cholangiocarcinoma. J Chir (Paris). 2004;141:315–321
  8. Martin R, Jarnagin W. Intrahepatic cholangiocarcinoma: Current management. Minerva Chir. 2003;58:469–478
  9. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–1357
  10. Bonney GK, Craven RA, Prasad R, Melcher AF, Selby PJ, Banks RE. Circulating markers of biliary malignancy: opportunities in proteomics?. Lancet Oncol. 2008;9:149–158
  11. Wang JH, Zhang WP, Liu HX, et al. Detection of human parvovirus B19 in papillary thyroid carcinoma. Br J Cancer. 2008;98:611–618
  12. Brown DC, Gatter KC. Ki67 protein: the immaculate deception?. Histopathology. 2002;40:2–11
  13. Angelopoulou R, Balla M, Lavranos G, et al. Evaluation of immunohistochemical markers of germ cells' proliferation in the developing rat testis: a comparative study. Tissue Cell. 2008;40:43–50
  14. Shi Z, Chen M, L He QL, Zeng JH. Antisense RhoC gene suppresses proliferation and invasion capacity of human QBC939 cholangiocarcinoma cells. Hepatobiliary Pancreat Dis Int. 2007;6:516–520
  15. Li Y, Wang J, Zhu G, et al. Detection of parvovirus B19 nucleic acids and expression of viral VP1/VP2 antigen in human colon carcinoma. Am J Gastroenterol. 2007;102:1489–1498
  16. Nakanuma Y, Sripa B, Vatanasapt V, Leong ASY, Ponchon T, Ishak KG. Intrahepatic cholangiocarcinoma. In:  Hamilton SR,  Aaltonen LA editor. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon, France: IARC Press; 2000;p. 173–180
  17. Hirohashi S, Ishak KG, Kojiro M, et al. Hepatocellular carcinoma. In:  Hamilton SR,  Aaltonen LA editor. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon, France: IARC Press; 2000;p. 159–172
  18. Dougherty JD, Garcia AD, Nakano I, et al. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase. J Neurosci. 2005;25:10773–10785
  19. Han C, Wu T. Cyclooxygenase-2-derived prostaglandin E2 promotes human cholangiocarcinoma cell growth and invasion through EP1 receptor-mediated activation of the epidermal growth factor receptor and Akt. J Biol Chem. 2005;280:24053–24063
  20. Tischoff I, Tannapfel A. Hepatocellular carcinoma and cholangiocarcinoma–different prognosis, pathogenesis and therapy. Zentralbl Chir. 2007;132:300–305
  21. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–813
  22. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol. 2007;23:317–323
  23. Lee WS, Lee KW, Heo JS, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36:892–897
  24. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol. 2002;33:1175–1181
  25. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006;49:138–151
  26. Van Eyken P, Sciot R, Paterson A, Callea F, Kew MC, Desmet VJ. Cytokeratin expression in hepatocellular carcinoma: an immunohistochemical study. Hum Pathol. 1988;19:562–568
  27. Wu PC, Fang JW, Lau VK, Lai CL, Lo CK, Lau JY. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications. Am J Pathol. 1996;149:1167–1175
  28. Wakasa T, Wakasa K, Shutou T, et al. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology. 2007;54:508–513
  29. Nandi A, Tidwell M, Karp J, Rapoport AP. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Blood Cells Mol Dis. 2004;32:240–245
  30. Nandi AK, Rapoport AP. Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF. Leuk Res. 2006;30:437–447
  31. Limaye PB, Bowen WC, Orr AV, Luo J, Tseng GC, Michalopoulos GK. Mechanisms of hepatocyte growth factor-mediated and epidermal growth factor-mediated signaling in transdifferentiation of rat hepatocytes to biliary epithelium. Hepatology. 2008;47:1702–1713
  32. Sirica AE, Gainey TW. A new rat bile ductular epithelial cell culture model characterized by the appearance of polarized bile ducts in vitro. Hepatology. 1997;26:537–549
  33. Lee CS, Pirdas A. Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours. Pathol Res Pract. 1995;191:1087–1091
  34. Batevik R, Grong K, Segadal L, Stangeland L. The female gender has a positive effect on survival independent of background life expectancy following surgical resection of primary non-small cell lung cancer: a study of absolute and relative survival over 15 years. Lung Cancer. 2005;47:173–181

PII: S0046-8177(09)00327-X

doi: 10.1016/j.humpath.2009.05.016

Human Pathology
Volume 41, Issue 3 , Pages 415-424 , March 2010

Article Tools

* Image Usage & Resolution